Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis
Top Cited Papers
Open Access
- 25 January 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Psychiatry
- Vol. 17 (3), 290-314
- https://doi.org/10.1038/mp.2010.136
Abstract
A comprehensive literature search was performed to collate evidence of mitochondrial dysfunction in autism spectrum disorders (ASDs) with two primary objectives. First, features of mitochondrial dysfunction in the general population of children with ASD were identified. Second, characteristics of mitochondrial dysfunction in children with ASD and concomitant mitochondrial disease (MD) were compared with published literature of two general populations: ASD children without MD, and non-ASD children with MD. The prevalence of MD in the general population of ASD was 5.0% (95% confidence interval 3.2, 6.9%), much higher than found in the general population (~0.01%). The prevalence of abnormal biomarker values of mitochondrial dysfunction was high in ASD, much higher than the prevalence of MD. Variances and mean values of many mitochondrial biomarkers (lactate, pyruvate, carnitine and ubiquinone) were significantly different between ASD and controls. Some markers correlated with ASD severity. Neuroimaging, in vitro and post-mortem brain studies were consistent with an elevated prevalence of mitochondrial dysfunction in ASD. Taken together, these findings suggest children with ASD have a spectrum of mitochondrial dysfunction of differing severity. Eighteen publications representing a total of 112 children with ASD and MD (ASD/MD) were identified. The prevalence of developmental regression (52%), seizures (41%), motor delay (51%), gastrointestinal abnormalities (74%), female gender (39%), and elevated lactate (78%) and pyruvate (45%) was significantly higher in ASD/MD compared with the general ASD population. The prevalence of many of these abnormalities was similar to the general population of children with MD, suggesting that ASD/MD represents a distinct subgroup of children with MD. Most ASD/MD cases (79%) were not associated with genetic abnormalities, raising the possibility of secondary mitochondrial dysfunction. Treatment studies for ASD/MD were limited, although improvements were noted in some studies with carnitine, co-enzyme Q10 and B-vitamins. Many studies suffered from limitations, including small sample sizes, referral or publication biases, and variability in protocols for selecting children for MD workup, collecting mitochondrial biomarkers and defining MD. Overall, this evidence supports the notion that mitochondrial dysfunction is associated with ASD. Additional studies are needed to further define the role of mitochondrial dysfunction in ASD.Keywords
This publication has 223 references indexed in Scilit:
- Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model for Angelman syndromeNeuroscience Letters, 2011
- Increased activities of Na+/K+-ATPase and Ca2+/Mg2+-ATPase in the frontal cortex and cerebellum of autistic individualsLife Sciences, 2009
- Novel plasma phospholipid biomarkers of autism: Mitochondrial dysfunction as a putative causative mechanismProstaglandins, Leukotrienes & Essential Fatty Acids, 2009
- Elevated immune response in the brain of autistic patientsJournal of Neuroimmunology, 2009
- The in-depth evaluation of suspected mitochondrial diseaseMolecular Genetics and Metabolism, 2008
- Intracerebroventricular injection of propionic acid, an enteric bacterial metabolic end-product, impairs social behavior in the rat: Implications for an animal model of autismNeuropharmacology, 2008
- Mitochondrial myopathy associated with a novel mutation in mtDNANeuromuscular Disorders, 2007
- Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autismNeuropsychiatric Genetics, Part B of the American Journal of Medical Genetics (AJMG), 2006
- Human Coenzyme Q10 DeficiencyNeurochemical Research, 2006
- Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stressMolecular Psychiatry, 2004